Maxim Group Initiates Coverage On Gain Therapeutics with Buy Rating, Announces Price Target of $10
Portfolio Pulse from Benzinga Newsdesk
Maxim Group analyst Jason McCarthy has initiated coverage on Gain Therapeutics (NASDAQ:GANX) with a Buy rating and a price target of $10.
September 12, 2023 | 1:50 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Maxim Group has initiated coverage on Gain Therapeutics with a Buy rating and a price target of $10.
The initiation of coverage by Maxim Group with a Buy rating indicates a positive outlook for Gain Therapeutics. The price target of $10 suggests that the analyst believes the stock has potential for growth. This could lead to increased investor interest and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100